4 ppbp

Compounds were purchased from the following sources: BD1063, 4-PPBP, and PF-04418948 from Tocris Biosciences (Minneapolis, MN); Haloperidol from Santa Cruz Biotechnologies, Inc. (Dallas, TX); Haloperidol metabolites I and II (4-(4-Chlorophenyl)-4-hydroxypiperidine and (±)-4-(4-Chlorophenyl)-α-(4-fluorophenyl)-4-hydroxy-1-piperidinebutanol, respectively) from Sigma-Aldrich (St. Louis, MO); Prostaglandin E₂ (PGE₂) from Cayman Chemical (Ann Arbor, MI). Radioligands were purchased from PerkinElmer: ([³H]-(+)-pentazocine ((+)-Pentazocine, [RING-1,3-³H], 33.9 Ci/mmol, NET1056), [³H]DTG (1,3-Di-o-tolylguanidine, [p-RING-³H]-, 50 Ci/mmol, NET986) (Saint Louis, MO). With the exception of PGE₂, which was dissolved in ethanol:water (1:1 v/v), stock concentrations of all compounds were prepared in DMSO at concentrations ranging from 10–100 mM. Stocks were then diluted 1:1000 (v/v) in the final assay solution. ProBDNF was from Alomone Labs (Cat. No. B-257, Jerusalem, Israel) and the source of the mature BDNF was from the BDNF standard provided in the Emax ImmunoAssay kit (Cat. No. G7611, Promega, Madison, WI).

Compounds were purchased from the following sources: 4-PPBP, BD1063, (+)-igmesine, PRE-084 from Tocris Biosciences (Minneapolis, MN); butamirate, carbetapentane, and NE-100 were from Santa Cruz Biotechnology (Dallas, TX); and donepezil oxeladin, promethazine was from Sigma-Aldrich (St. Louis, MO). Radioligands were purchased from PerkinElmer: ([³H] - (+)-pentazocine ((+)-Pentazocine, [RING-1,3-³H], 33.9 Ci/mmol, NET1056), [³H]-DTG (1,3-Di-o-tolylguanidine, [p-RING-³H]-, 50 Ci/mmol, NET986) (Saint Louis, MO). All compounds were prepared in DMSO at concentrations ranging from 10–100 mM. Stocks were then diluted 1:1000 (v/v) in the final assay solution.